Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) – Investment analysts at Roth Capital boosted their Q3 2025 EPS estimates for Revelation Biosciences in a research note issued to investors on Monday, September 15th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($1.05) per share for the quarter, up from their prior estimate of ($1.56). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($49.33) per share. Roth Capital also issued estimates for Revelation Biosciences’ Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($5.31) EPS, FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($1.43) EPS, FY2028 earnings at $0.83 EPS and FY2029 earnings at $2.05 EPS.
Separately, Wall Street Zen upgraded shares of Revelation Biosciences to a “sell” rating in a research report on Friday, June 27th.
Revelation Biosciences Stock Performance
Shares of Revelation Biosciences stock opened at $1.56 on Thursday. Revelation Biosciences has a fifty-two week low of $1.50 and a fifty-two week high of $60.48. The firm has a 50-day simple moving average of $2.57 and a two-hundred day simple moving average of $5.38. The company has a market cap of $3.65 million, a P/E ratio of -0.02 and a beta of -0.04.
Revelation Biosciences (NASDAQ:REVB – Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($7.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.46) by ($2.55).
Revelation Biosciences Company Profile
Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
Featured Stories
- Five stocks we like better than Revelation Biosciences
- There Are Different Types of Stock To Invest In
- Why Seagate Is Wall Street’s New Favorite AI Infrastructure Play
- Stock Splits, Do They Really Impact Investors?
- 3 AI Infrastructure Stocks With Upside After the Summer Rally
- Top Stocks Investing in 5G Technology
- Can Advantage2 Help Overcome D-Wave’s Share Price Plateau?
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
